Leukemia News

Standard cancer care may fail to adequately address the needs of LGBTQ+ individuals, who face substantial disparities in access to screening, treatment and outcomes.

COVID-19 variants pose a greater threat to certain patients with cancer, particularly those with hematologic malignancies, confirming the need to promote vaccination within this population, according to data presented at ESMO Congress 2021.

The FDA cleared an investigational new drug application for NTLA-5001, a T-cell receptor T-cell therapy designed to treat adults with relapsed or refractory acute myeloid leukemia.

The FDA granted fast track designation to VOR33, an engineered allogeneic stem cell therapy for the treatment of patients with acute myeloid leukemia who are at high risk for relapse.

The FDA approved the first chimeric antigen receptor therapy in 2017, authorizing tisagenlecleucel for treatment of children or young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

Renier Brentjens, MD, PhD, has been appointed deputy director and chair of the department of medicine of Roswell Park Comprehensive Cancer Center.

The addition of pevonedistat to azacitidine for first-line treatment of certain patients with blood cancers failed to extend EFS, according to topline data released by the agent’s manufacturer.

Age and ethnic background appeared associated with inadequate follow-up care among young adult childhood cancer survivors, according to study results published in JNCI Cancer Spectrum.

Accounting for the benign rs2814778-CC genotype when considering a bone marrow biopsy could avoid unnecessary procedures, particularly in African American patients, according to findings published in JAMA Internal Medicine.

National Comprehensive Cancer Network updated its guidance on COVID-19 vaccination for patients with cancer following FDA authorization of a third mRNA vaccine dose for certain immunocompromised individuals.